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Regenerative medicine has been endorsed in Spain as a strategic, interdisciplinary topic to boost biomedical
research. Special programs have been developed to promote collaborative research efforts among Spanish
basic, applied, translational, and clinical researchers. Here, we present what we consider Spain’s main
current assets in this area.Many readers may associate Spain with
a delightful vacation place and a paradise
for the arts and culture, rather than with
a source of competitive science, let alone
high-class biomedical research. This im-
age is fortunately changing, and Spain is
beginning to occupy a place in the world-
wide research and development picture
more consistent with her economic,
social, and cultural position. Spain’s repu-
tation is evolving in a variety of scientific
areas, of which stem cell research is
a good example and, coincidentally,
a strategically chosen driving paradigm.
In the early 2000s, Spain, like many
other developed countries, engaged in
intense social and political debate over
the use of human embryos for research.
As the first human embryonic stem cell
(ESC) lines were derived in James Thom-
son’s laboratory and their great promise
was widely publicized, Spanish policy-
makers faced the dilemma of whether
such research should be allowed. At the
time, a surplus of well over 50,000 human
embryos derived during in vitro fertiliza-
tion (IVF) treatments had accumulated
and were kept frozen, with no clear destiny.
Social perception was largely in favor of
allowing the use of such embryos for
research, including thederivationofhESCs,
and in 2003 the then-ruling People’s
Party passed an Assisted Reproduction
Techniques law (45/2003) that permitted
embryos that had been frozen prior to that
date to be donated for use in research.
Although the main aim of this law was to
prevent the accumulation of frozen human
embryos in IVF clinics, the new legislation
opened the door for hESC research and,quite significantly, suggested that the
stem cell debate would not create the polit-
ical divide in Spain that it has in other coun-
tries. In any case, the law was short lived,
for 4 months later a new government led
by the Socialist Party was elected, which
had announced among their priorities
the large-scale promotion of regenerative
medicine research in Spain.
Current Regulatory Framework
The new government has since passed two
new laws that are considered less restric-
tive than the original 2003 rulings and define
the existing legislative framework for hESC
derivation and research in Spain. The first
law (14/2006) updates the original Assisted
Reproduction Techniques ruling and
requires that couples with surplus frozen
embryos following IVF treatment, regard-
less of the time of cryopreservation, are
presented with four options: keeping them
frozen for their own subsequent reproduc-
tive use, donation to other couples for
reproduction, donation for a specific
researchproject, ordisposal without further
use. The second law is broader (Spanish
Law on Biomedical Research, 14/2007)
and explicitly prohibits the creation of
human embryos for research purposes
but allows the derivation of hESCs for
research or therapy using any technology
(such as nuclear transfer) that does not
involve fertilization to generate viable
embryos. In summary, Spain currently has
one of the most progressive legislations
worldwide with respect to hESC research.
In addition to providing a new regulatory
framework, the changes in legislation
brought about specific instruments toCell Stemcontrol the derivation and use of hESCs
and to promote regenerative medicine
research. Thus, the Carlos III Health Insti-
tute (the Spanish counterpart of the NIH
in the US, then dependent on the Ministry
of Health and now under the auspices of
the Ministry of Science and Innovation)
created the position of Subdirectorate-
General for Research in Cell Therapy and
Regenerative Medicine with the aim of
harmonizing strategic stem cell research
interests and their ethical and legal implica-
tions. Toward this end, the Subdirectorate-
General oversees the Commission on
Guarantees concerning the Donation and
Use of Human Tissues and Cells, which
monitors and controls all research projects
that generate or use hESCs in Spain. The
Commission is comprised of 12 members
withproven expertise in stem cell research,
bioethics, or biomedical law, and who are
appointed to 3-year terms of service. This
all-powerful Commission provides a regu-
latory solution that is sufficiently flexible
to cope with the rapidly changing field of
stem cell research (Rugg-Gunn et al.,
2009), in that issues not explicitly covered
or foreseen by the Law on Biomedical
Research (for instance, the injection of
hESCs into mouse blastocysts, the gener-
ation ofcybrids,or the generationof human
iPSCs) can be dealt with by the Commis-
sion on a project-by-project basis.
The National Stem Cell Bank
The Subdirectorate-General for Research
in Cell Therapy and Regenerative Medi-
cine is also tasked with promoting stem
cell research in Spain, and perhaps the
most significant initiative undertaken toCell 4, June 5, 2009 ª2009 Elsevier Inc. 483
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National Stem Cell Bank (BNLC). The
BNLC was established as a multinode
network structure designed to ensure
that hESC derivation is conducted ac-
cording to strict legal, ethical, and scien-
tific guidelines, and that the lines gener-
ated are made available to researchers
nationwide. In concert with financing
from and oversight by the governments
of Autonomous Communities Catalonia,
Andalusia, and Valencia (Spain is made
up of 17 regions and nationalities, known
as Autonomous Communities, with ample
self-government competences, including
healthcare and research), three BNLC no-
des were created: in Barcelona, under the
direction of Anna Veiga; Granada, under
the direction of Pablo Mene´ndez; and Va-
lencia, under the direction of Carlos
Simo´n. Based on their locations and
stem cell research-promoting initiatives
from the regional governments, the indi-
vidual nodes of the BNLC will be inte-
grated into (or linked with) newly created
research centers such as the Center
for Regenerative Medicine in Barcelona
(CMRB), the Andalusian Molecular Bio-
logy and Regenerative Medicine Centre
(CABIMER) in Seville, and the Prince Fe-
lipe Research Centre (CIPF) in Valencia.
Needless to say, research projects
involving derivation of hESC lines at the
BNLC nodes require prior approval by
the Commission on Guarantees concern-
ing the Donation and Use of Human
Tissues and Cells. In principle, doing
things the right way in Spain implies
countless layers of paperwork. In the
case of hESC derivation, it took more
than 5 years of passing laws, creating
commissions and more commissions,
and setting up banks and nodes. In the
end, Spanish researchers entered quite
late into the hESC research race, finally
getting the green light in mid-2005.
However, the extra effort led to a solid,
yet flexible legislative framework that will
accommodate new scientific develop-
ments and a national commitment to an
ambitious, long-term research program.
The first five fully characterized Spanish
hESC lines were deposited in the BNLC
in November 2006. Since that time, at
least six more lines have been deposited
and have been distributed to dozens of
researchers in Spain and elsewhere.
The BNLC acts as a repository of hESC
lines derived in Spain but does not intend484 Cell Stem Cell 4, June 5, 2009 ª2009 Elto become a comprehensive banking
service or to compete with other initiatives
such as the UK Stem Cell Bank. Indeed,
this goal would prove very difficult due
to the range of national regulatory policies
and the fragmented information available
as to the origin and characteristics of ex-
isting hESC lines. Realizing these prob-
lems, the European Commission backed
the development of the Human Embry-
onic Stem Cell Registry (hESCreg), coor-
dinated by Anna Veiga, from the CMRB,
and Joeri Borstlap, from the Berlin-Bran-
denburg Center for Regenerative Thera-
pies (Borstlap et al., 2008). Currently, the
hESCreg contains detailed information
regarding the derivation, molecular char-
acteristics, use, and quality of 645 hESC
lines, 191 of which are freely available to
researchers.
Spain’s Main Assets
The majority of scientific output in Spain,
by volume, comes from Universities and
from the Spanish National Research
Council (CSIC), which is composed of
multiple public research centers. Both
institutions are undergoing profound
organizational changes aimed to solve
their deeply rooted problems in flexibility
and competitiveness. Nevertheless, there
are at least three research areas related to
stem cell biology in which these more
traditional settings have managed to
excel, including neuroscience, develop-
mental biology, and gene therapy. The
heritage of Santiago Ramo´n y Cajal is
evident in the many excellent neurosci-
ence laboratories scattered throughout
Universities and CSIC centers. These
groups have made many important contri-
butions to stem cell research, such as the
identification of multipotent, glia-like stem
cells in the adult carotid body (by the labo-
ratory of Jose´ Lo´pez Barneo at the Univer-
sity of Seville) and their potential use for
cell therapy of Parkinson’s disease (Par-
dal et al., 2007), or the characterization
of pigment epithelium-derived factor
(PEDF) as a crucial niche-derived factor
that regulates the self-renewal of neural
stem cells (Ramirez-Castillejo et al.,
2006). The school of developmental
biology, created by Antonio Garcı´a Bellido
and expanded by Gine´s Morata (both at
the CBMSO, Madrid), gave rise to many
talented disciples distributed across
Spain and has provided valuable insights
into the cellular and molecular mecha-sevier Inc.nisms that control cell differentiation.
Finally, a sizable critical mass of compet-
itive laboratories working in gene therapy
research has been assembled in Spain
over the past 15 years. Hematopoietic
stem cells have been the preferred exper-
imental model, and the resulting combi-
nation of gene and cell therapy tools has
contributed strongly to the present state
of the art of stem cell research in Spain.
In fact, the Spanish Gene Therapy Associ-
ation changed its name in 2007 to Spanish
Association of Cell and Gene Therapy and
now includes a full chapter dedicated to
stem cell research. These laboratories
make up an invaluable culture broth for
the formation of new generations of well-
trained scientists, most of whom, unfortu-
nately, pursue their careers elsewhere.
During the last 10 years, a new type of
research institution has emerged in Spain
to forestall the problems of inflexibility,
bureaucracy, lethargy, and inbreeding
that burden university- and CSIC-driven
research. These centers have in common
the legal entity of independent, nonprofit
private foundations with their own ad-
ministration and minimal bureaucracy,
a scientific direction with ample decision
powers, flexibility in hiring conditions, and
evaluation systems based on merit. Two
such centers were created in Madrid by
the Carlos III Health Institute: the National
Cancer Research Centre (CNIO), directed
by Mariano Barbacid, and the National
Center for Cardiovascular Research
(CNIC), directed by Valentı´n Fuster. This
new model of research center has been
used extensively in Catalonia, where 38
new centers and institutes have been
created in all areas of science. Specially
relevant for stem cell research are the
CMRB, directed by me (J.C.I.B.); the
Centre for Genomic Regulation (CRG),
directed by Miguel Beato, which has at-
tracted Thomas Graf to coordinate the
Differentiation and Cancer Program; the
Institute for Research in Biomedicine (IRB
Barcelona), directed by Joan Guinovart
with Joan Massague´ as Adjunt Director;
the Catalan Institute of Cardiovascular
Sciences (ICCC), directed by Lina Ba-
dimo´n; the Vall d’Hebron Institute of
Oncology (VHIO), directed by Josep Base-
lga; and the Institute for Bioengineering of
Catalonia (IBEC), directed by Josep Pla-
nell. In other areas of Spain, similar centers
have been created to catalyze biomedical
research, such as CIC bioGUNE, directed
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the CIPF in Valencia, directed by Rube´n
Moreno, which has attracted Miodrag Stoj-
kovic to lead their program in regenerative
medicine; and the Institute for Biomedicine
in Seville (IBIS), directed by Jose´ Lo´pez
Barneo. This explosion of new, dynamic,
well-equipped, and highly specialized
research centers is one of Spain’s main
assets that will help make a difference in
the field of stem cell research. Proof that
the flexibility bestowed upon these new
centers is successful is seen in their recent
contributions to the field of induced pluri-
potency, arguably the most active and
competitive topic of stem cell research at
the moment. These advances include
studies at the CMRB generating the first
human iPSC lines in Europe (Aasen et al.,
2008) and providing proof of concept that
disease-free progenitor cells with potential
value for cell therapy can be obtained from
patient-specific iPSCs (Raya et al., 2009);
analyses at the CRG on the retroviral inser-
tion sites of mouse iPSCs that challenged
the importance of insertional effects for re-
programming (Varas et al., 2009); and work
at the CNIO on the dynamics of telomere
elongation during reprogramming, which
highlighted the importance of telomerase
for iPSC generation (Marion et al., 2009).
While the overall performance of Spanish
biomedical research still lags behind that
of the major international players, clinical
research fares remarkably well in most
comparisons. For instance, papers on clin-
ical medicine by Spanish authors indexed
by Thomson Reuters between 2003 and
2007 received an average of 2.69 citations
per paper, an impact 11% above the world
average. A recent example of the accom-
plishments of translational research in
Spain, particularly relevant for regenerative
medicine, was the successful transplanta-
tion of a tissue-engineered trachea per-
formed at the Hospital Clinic in Barce-
lona (Macchiarini et al., 2008). Multiple
circumstances converge to determine the
strength of Spanish clinical research,
including a high-quality healthcare system
that provides universal coverage, well-
developed structures and logistics associ-
ated with translational research and clinical
trials, the strong support and active role
played by private companies, and most
important, the professionalism and dedica-
tion of physicians and nurses engaged in
clinical research. Many Spanish clinical
researchers are among the world leadersin their fields, such as Francisco Ferna´n-
dez-Avile´s (Hospital Gregorio Maran˜on,
Madrid) in myocardial infarction, Eduard
Tolosa (Hospital Clı´nic, Barcelona) in
Parkinson’s disease, Teresa Go´mez-Isla
(Santa Cruz y San Pau Hospital, Barcelona)
in Alzheimer’s disease, Joan Rode´s
(HospitalClı´nic, Barcelona) in liver cirrhosis,
Ramon Gomis (Hospital Clı´nic, Barcelona)
in diabetes, Josep Baselga (Hospital Vall
d’Hebron, Barcelona) in oncology, and
Damia´n Garcı´a-Olmo (Hospital La Paz, Ma-
drid) in general surgery. Where applicable,
Spanish clinical researchers are willing to
consider strategies of regenerative medi-
cine (Fernandez-Aviles et al., 2004; Gar-
cia-Olmo et al., 2005). A tightly networked
healthcare system of excellence, with
some 40.5 million potential users and
a large number of highly trained profes-
sionals (3.4 practicing physicians per 1000
inhabitants, versus 3.0, the Organisation
for Economic Co-operation and Develop-
ment average), is a key asset for Spain’s
contribution to bringing the advances in
stem cell research into clinical practice.
The success of the Spanish National Trans-
plantation Organization (ONT) illustrates
the immense potential of the Spanish
healthcare system when working in unison.
Created in 1989 to promote organ trans-
plantation in Spain, the ONT, under the
leadership of Rafael Matesanz, managed
to coordinate all parties involved to more
than double the donation rate to the highest
in the world. The working model of the ONT
(known as the Spanish model) is now the
reference model for organ transplantation
coordination and policies worldwide.
Remarkably, the success of the ONT
requires a comparatively low investment
(a current annual budget of 4.2 million
euro for around 40 staff), highlighting the
cost-effectiveness of good coordination
and networking once the key elements
are in place. On a wider scale, in 2006
the Carlos III Health Institute launched
an ambitious program to promote collab-
orative research in biomedicine among
basic, applied, and clinical scientists.
Around 500 research groups were
selected based on their track record to
form 18 Thematic Networks of Coopera-
tive Health Research (RETICS). Stem cell
research is explicitly covered in the Cell
Therapy Network (TERCEL). Similarly,
almost 400 groups were selected to
create nine virtual Networking Centers of
Biomedical Research (CIBER), which areCell Stemlegal entities that provide additional
administrative and operational flexibility.
In addition, to capitalize on the strength
of clinical research in Spain, the Carlos
III Health Institute has initiated a process
to accredit hospitals of excellence with
Health Research Institutes, which will be
eligible for additional funding. Five such
institutes have been sanctioned so far,
nucleated around Hospital Clı´nic, Ho-
spital Vall d’Hebro´n, Hospital Bellvitge,
and Hospital Germans Trias i Pujol (all of
them in the Barcelona area), as well as
Hospital Virgen del Rocı´o in Seville.
The Challenge Ahead
While collaborative research among
Spanish groups has become the norm,
international collaboration is, unfortu-
nately, still the exception, and even more
so when private companies are involved.
The 2008 edition of the Eurostat report
on ‘‘Science, technology and innovation
in Europe’’ places Spain as the country
with the least innovation cooperation at
European and international levels. This
trend must be corrected if Spanish
research initiatives and networks are to
succeed in the worldwide biomedical
picture. While the Cooperation Pro-
gramme of the European Commission
(EC) has drastically changed the collabo-
ration patterns in many areas of biomed-
ical research, this impact has yet to be
seen in human pluripotent stem cell
research, due to the traditionally timid
approach of the EC toward hESCs, given
the diversity in national legislation and
sensibilities (Winston, 2007). On the other
hand, Spain is beginning to attract signif-
icant numbers of foreign researchers to
conduct postdoctoral studies, but the
positive results of these interactions in
terms of international collaborations will
take several years to realize. In the mean-
time, it is imperative that specific policies
are put in place to foster international
collaborative research projects. An im-
portant initiative in this direction has
been taken very recently by the Spanish
Ministry of Science and Innovation
(MICINN), which has allocated 10 million
euro to a joint funding call with the Califor-
nia Institute for Regenerative Medicine
(CIRM) to support collaborative projects
between Spanish and Californian groups.
This venture is allegedly the first in a series
of international collaboration agreements
that will comprise the MICINN’s ambitiousCell 4, June 5, 2009 ª2009 Elsevier Inc. 485
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Regenerative Medicine.
We can only hope that the necessary
steps to secure Spain’s position in the
biomedical research landscape are not
deterred this time by the current worldwide
situation of economic and financial crisis.
This risk, in combination with Spain’s track
record, is the inspiration for the title of this
article. This is certainly a generalization,
but the Spanish approach to problem-
solving tends to swing between two
extremes: an unwavering and almost
heroic determination to resolve a situation
(real or otherwise) that is seemingly unsolv-
able, and the complete and unashamed
neglect of problems that prove to be diffi-
cult to solve. These extremes are epito-
mized by, on the one hand, Don Quixote’s
ferocious attacks on the windmills that he
perceived to be giants, and on the other,
by the infamous exclamation by renowned
Spanish writer Miguel de Unamuno, in
reference to the national technological
impasse: ‘‘Let others invent!’’ Peculiar to
Spain is that both extremes are often
pursued, alternatively, by a given individual
or community with respect to the same
problem. Indeed, this duality is more trou-
bling when exhibited by policymakers,
a situation that is not infrequent. All too
often, the priority of modernizing Spanish
biomedical research has been put aside486 Cell Stem Cell 4, June 5, 2009 ª2009 Ein favor of more urgent needs (the consoli-
dation of the ‘‘national spirit’’ under Fran-
co’s dictatorship, the economic crisis of
the 1970s, the efforts to enter the European
Community, the economic crisis of 1991–
92, and the adaptation of the common
European currency, to name a few). This
time, we really are facing giants. A giant
effort has been made in the past 10 years
to modernize Spanish biomedical re-
search. Giant results may be achieved if
the different strategic initiatives are given
time to come to fruition. Giant benefits for
society at large can come by developing
safe and efficient strategies of regenerative
medicine. Since we are not likely to change
the Spanish habit of running away from true
giants, let us pretend, just for this situation,
that they are only windmills.
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